Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 5Phase 2 5Phase 4 4Phase 1 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Paclitaxel-induced Neuropathy 1Mesothelioma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Magnesium Sulfate × Clear all
NCT04481672 2022-01-11

Intravenous Magnesium in Patients Receiving Cisplatin

Dana-Farber Cancer Institute

Phase 1 Completed
5 enrolled
Other solid neoplasmThoracic

Mesothelioma

NCT01682499 2014-09-25

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

Beth Israel Medical Center

Phase 1 Completed
50 enrolled

Paclitaxel-induced Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡